Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $128,044.80 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total transaction of $128,044.80. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at $546,680.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Christine Ring also recently made the following trade(s):

• On Tuesday, September 3rd, Christine Ring sold 9,050 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.94, for a total transaction of $225,707.00.
• On Monday, August 26th, Christine Ring sold 9,870 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.01, for a total transaction of $246,848.70.
• On Thursday, August 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $21.43, for a total transaction of $123,436.80.

Nurix Therapeutics Stock Down 1.4 %

Shares of NRIX opened at $21.67 on Friday. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -7.42 and a beta of 2.22. The company’s fifty day moving average is $23.17 and its 200-day moving average is $18.82. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $26.31.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The business had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after purchasing an additional 3,424 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Nurix Therapeutics during the 1st quarter worth $123,000. China Universal Asset Management Co. Ltd. grew its stake in Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after buying an additional 3,793 shares during the last quarter. ProShare Advisors LLC raised its holdings in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after acquiring an additional 998 shares during the period. Finally, Dark Forest Capital Management LP acquired a new position in Nurix Therapeutics during the 2nd quarter worth $201,000.

Analyst Ratings Changes

NRIX has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Needham & Company LLC lowered their target price on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, July 12th. Oppenheimer increased their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 4th. Royal Bank of Canada boosted their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday, July 12th. Finally, Barclays increased their target price on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $27.00.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.